UroGen Pharma Aktie
WKN DE: A2DTCV / ISIN: IL0011407140
28.07.2025 15:30:49
|
UroGen Pharma Publishes Phase 3b Study Data Showing The Feasibility Of Home Instillation Of ZUSDURI
(RTTNews) - UroGen Pharma Ltd. (URGN) Monday announced the publication of data from Phase 3b study evaluating the feasibility of at-home instillations of ZUSDURI in patients with recurrent non-muscle invasive bladder cancer (NMIBC) in Reviews in Urology.
In this study, ZUSDURI was administered via urinary catheter. Investigators found no meaningful differences between home and office instillation for most patients. The safety profile was consistent with previous studies, with most adverse events being mild-to-moderate urinary symptoms.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu UroGen Pharma Ltd Registered Shsmehr Nachrichten
06.08.25 |
Ausblick: UroGen Pharma informiert über die jüngsten Quartalsergebnisse (finanzen.net) |
Analysen zu UroGen Pharma Ltd Registered Shsmehr Analysen
Aktien in diesem Artikel
UroGen Pharma Ltd Registered Shs | 16,60 | 3,75% |
|